Biotech-Star BioNTech aus Mainz

nächste Termine für news sollten diese sein:

a) ab Montag  June 22 - 24, 2020 |
The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research and highlights the work of the best minds in research and medicine from institutions all over the world.

BNT122 Phase 1/2 trial update expected at AACR Virtual Annual Meeting II in June
link:  https://investors.biontech.de/news-releases/...financial-results-and/

b) Freitag,  June 26, 2020
BioNTech SE Annual General Meeting (virtual)
Due to the coronavirus pandemic, the AGM had to be rescheduled and will be held virtually.
link:    https://investors.biontech.de/events-presentations
 

ich habe genauer hingeschaut, wann die BioNTech Vorträge bei der AACR Konferenz stattfinden:

Session VM2PO.CT01 - Phase I Clinical Trials
Montag 22.06 ab 15:00 CEST (ganztägige Session)
Phase 1a Ergebnisse BNT122

Session CTPL01 - Clinical Trials Plenary
Dienstag 23.06 ab 15:05-15:15 CEST
Phase 1b Ergebnisse BNT122

Session MW10 - Cancer Vaccines
Dienstag 23.06 ab 22:30 CEST
Invited Speaker Presentation - Herr Ugur Sahin, BioNTech AG, Mainz, Germany  

H.C. Wainwright analyst Robert Burns
Artikel ist von Ende Mai aber noch topaktuell......siehe link unten.... Auszüge:

All of the above reasons prompted Burns to upgrade BioNtech from Neutral to Buy, and raise the price target from $48 to $69. Investors stand to pocket a 34% gain should the analyst’s thesis play out over the coming months.

However, Burns argues BioNTech’s platform has “certain advantages vs. Moderna’s approach.”
BioNTech and Pfizer are working together to evaluate four different BNT162 mRNA vaccine candidates. Two of which have nucleoside-modified mRNA (modRNA), one has uridine-containing mRNA (uRNA) and the fourth candidate makes use of self-amplifying mRNA (saRNA).

“We see advantages to using a uRNA or saRNA backbone over a modRNA approach (e.g., Moderna’s approach). These include a stronger CD8 T-cell response with a uRNA backbone and the potential for longer-term immunogenicity with a saRNA backbone,” Burns opined.

Nevertheless, Burns sees mRNA-1273’s initial positive data as good news for BNT162, with it raising “the probability of approval for BNT162 to 35% from the prior 20%.” It should be noted that initial Phase 1 data for BNT162 is expected in June or July.

link:
https://www.tipranks.com/news/corona/...-up-on-modernas-says-analyst/  

Werden die Abstracts auch am 22.06. veröffentlicht?  

Ohne Kommentierung
Link:
https://www.bullbearbres.com/post/flash-biontech-aacr-2020  

https://www.evaluate.com/vantage/articles/events/...e-cancer-vaccines  

Kritik an chinesischem Corona-Impfstoff von CanSino  inige Nebenwirkungen und eine Technik, die schon bei HIV scheiterte - der Impfstoff von CanSino-Biologics ist weit entwickelt, aber "bedenklich", so Experten.

link:  https://www.tagesspiegel.de/wissen/...-corona-impfstoff/25936428.html  

AACR Virtual Annual Meeting 2020: Personalised cancer vaccine shows promise in early trial

link:
https://www.icr.ac.uk/news-archive/...ne-shows-promise-in-early-trial  

Amis prügeln den Kurs nicht runter!  

 

 

Haben wir Moderna und Novavax ja sogar mal im Schatten stehen gelassen:-D  

 

Im Novavax Forum habe ich von Kursen von 100 und 150 Euro gelesen könnte ja sein.
Ich finde das BioNTech besser aufgestellt ist wie Moderna und Novavax.
Meine Begründung dafür ist das BioNTech gleich vier Impfstoffe laufen hat.
Hier warten die Meisten auf die Covid news und die kommt bald.  

aufgestellt ist , keins dieser unternehmen wird wahrscheinlich ein corona impfstoff entwickeln , es gibt bis heute kein impfstoff für Aids -

Es kommt auf hoffnung an , an vermarktung und den willen der Aktionäre den kurs kurz zu pushen

ich für meinen Teil denke 70 € raus aber muss jeder selbst wissen

vielleicht haben sie den 1 million Dollar treffer und finden was gegen Corona dann sind kurse von 100 € zu Billig , aber setzen würde ich nicht haus und hof siehe wirecard

daraus sollte jeder lernen nicht sein leben in unternehmen stecken die man nicht kennt also ich kenn die chefs dort nicht warum sollte ich allso meine ganze Kohle dort rein stecken mehr als 5 % laufen da nicht drin bin ja nicht geisteskrank dann kann ich gleich ins casino gehen  

June 19, 2020AACR 2020 – Biontech and Roche try to resuscitate cancer vaccines

A first-in-human study of the companies’ neoantigen mRNA cancer vaccine fails to rewrite these agents’ poor history.

It is surely a measure of cancer vaccines’ abysmal track record that a mere 7% overall response rate is enough for a spotlight at an oncology conference. Step forward RO7198457, a personalised neoantigen vaccine in development by Roche and Biontech, the first human data on which have just been unveiled at this year’s second virtual AACR meeting.

However, despite being highlighted at a pre-meeting press conference, results of a phase I multi-tumour study have shown RO7198457 plus Tecentriq to have “modest activity in the heavily pretreated dose-escalation patient population”, admitted Dr Juanita Lopez of Royal Marsden NHS Foundation trust. Some investors will come away wanting to have seen better.

But Dr Lopez insisted that the trial had at least one important aspect, saying: “The thing I’m most excited about is that we’ve managed to show that in the majority of patients we were able to elicit a specific immune response.” It is more typical for an immune response to fail to be initiated, as evidenced by no immune cells being seen within the tumour.

In the trial’s Tecentriq combo cohort neoantigen-specific T-cell responses induced by the vaccine were observed in 46 of 63 subjects. In a RO7198457 monotherapy cohort, detailed in a separate AACR presentation, T-cell responses were observed in the peripheral blood of 14 of 16 patients.

Not sufficient?

However, Dr Lopez accepted that “this in itself may not be sufficient”.

RO7198457 monotherapy yielded just one, complete, response in 26 evaluable subjects, while in combo with Tecentriq there were eight partial and one complete remission in 108 evaluable patients. One reason for the poor efficacy suggested by Dr Lopez was that subjects had been heavily pretreated, with a median three prior therapies.

It is not at all clear how many subjects might have responded with Tecentriq alone, and Dr Lopez would not indulge in cross-trial comparisons. 39% of the patients entering the combo cohort had failed immunotherapy, but she would not say what the percentage was for the nine responders.

Dr Lopez did detail two remissions, one partial, one complete, in an initial dose escalation: the first was checkpoint-experienced and PD-L1-high, but the second was neither. Further data will be presented on Tuesday.

Source: Dr Juanita Lopez & AACR.

RO7198457, also known under the codes RG6180 and BNT122, is the first project to emerge from a deal Roche and Biontech had struck back in 2016. This, of course, was before Biontech floated and was able to bask in its current $11bn valuation, which is largely the result of its efforts to develop an mRNA vaccine against Covid-19.

Two clinical trials of RO7198457 are now under way: the phase I dose-escalation study just unveiled at AACR, and a phase II trial called Imcode-001, in combination with Merck & Co’s Keytruda in front-line melanoma, which started a year ago. The companies also plan two randomised studies in resected lung and colorectal tumours.

Conceptually RO7198457 is anything but simple, having to be manufactured on a per-patient basis. Each patient’s tumour is analysed and sequenced to identify about 20 neoantigens, for which corresponding mRNA is generated and encapsulated in a liposome that is then injected with the aim of eliciting an immune response.

It is promising that evidence of the mechanistic rationale for such an approach has been shown. But, unless T-cell responses translate into clinical remissions, cancer vaccines will not have a future  

... dass der Curs gleich abhebt ...

Wieso gehst du davon aus?  

... zu wollen, wenn auch zunächst nur moderat ...

Ist die Biontech schon abgehoben?  

Noch eine gute Nachricht zu den Studien kommt heben wir richtig ab. Bin angeschnallt schon und der Tisch ist eingeklappt:-D  

Aja... Aktien steigen in der Regel langfristig immer - es sei denn man heißt Wirecard.
Wäre schon schön, wenn du deine Aussagen auch mit mehr fundierten Informationen teilst.  

sieht verdammt gut aus, ich schätze die rakete geht wirkliuch gleich los  

... "Fundamentaliste", sondern ganz ausschließlich Chartist !

Kann deshalb mit irngswas "Fundiertem" nicht dienen,
sondern lediglich mit der - rechtzeitigen - Ansage, ob ein Curs demnächst steigt oder fällt ...